Mylan Prepares To Launch Canada's First Trastuzumab Within Weeks
By the end of June, Mylan expects to have launched in Canada the Ogivri trastuzumab 150mg and 440mg vials for which it has just received regulatory approval.
You may also be interested in...
Samsung Bioepis Gets Canadian Trastuzumab Nod
Samsung Bioepis has received approval from Health Canada for its Ontruzant trastuzumab biosimilar rival to Herceptin in 150mg single-use and 440mg multi-dose vials. The product will be marketed in Canada by Organon.
Mylan And Biocon Launch Fulphila In Canada
Mylan and Biocon have introduced the second biosimilar pegfilgrastim rival to Neulasta in Canada with the launch of their Fulphila version.
Celltrion And Teva Catch Up On Canadian Trastuzumab
Celltrion and Teva have now received a Health Canada approval for their Herzuma trastuzumab biosimilar. However, notices of compliance have already been granted for rival biosimilars from Mylan and Pfizer.